General Information


We are a clinical-stage biotechnology company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. We believe we are the leader in the field of SEMA4D biology and that we are the only company targeting SEMA4D as a potential treatment for cancer, neurodegenerative diseases, or autoimmune disorders. SEMA4D is an extracellular signaling molecule that regulates the migration of immune and inflammatory cells to sites of injury, cancer or infection.

Employees: 44
Founded: 2001
Contact Information
Address 1895 Mount Hope Avenue, Rochester, NY 14620, US
Phone Number (585) 271-2700
Web Address
View Prospectus: Vaccinex
Financial Information
Market Cap $137.7mil
Revenues $0.3 mil (last 12 months)
Net Income $-24.1 mil (last 12 months)
IPO Profile
Symbol VCNX
Exchange NASDAQ
Shares (millions): 3.3
Price range $12.00 - $12.00
Est. $ Volume $40.0 mil
Manager / Joint Managers Oppenheimer/ BTIG
CO-Managers Ladenburg Thalmann
Expected To Trade: 8/9/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change